Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30616153 | 1.00 | LMNA (0.48) | LMNASMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL29092878 | 1.00 | LMNA (0.48) | LMNASMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL25800370 | 0.91 | HDAC1 (0.42) | LMNASMN1; SMN2HDAC1HDAC2ALDH1A1 | |
| SCHEMBL9915159 | 0.90 | HDAC1 (0.42) | LMNASMN1; SMN2HDAC1HDAC2KMT2A | |
| SCHEMBL20998952 | 0.85 | ALDH1A1 (0.45) | LMNASMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL24360385 | 0.85 | ALDH1A1 (0.45) | LMNASMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL10581036 | 0.80 | LMNA (0.52) | LMNASMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL8315368 | 0.79 | LMNA (0.50) | LMNASMN1; SMN2HDAC1MEN1KMT2A | |
| SCHEMBL9915144 | 0.78 | RAB9A (0.46) | LMNASMN1; SMN2HDAC1HDAC2GAA | |
| SCHEMBL24378432 | 0.77 | HDAC1 (0.48) | SMN1; SMN2HDAC1HDAC2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940570-A | Compounds and methods for treating ocular disorders | 阿祖拉眼科有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | LMNA 1643/4885SMN1; SMN2 4754/4885HDAC1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.